|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-6-20
|
|
pubmed:abstractText |
EGFRvIII has been described to function as an oncoprotein with constitutive activation promoting neoplastic transformation and tumorigenicity. The present study was undertaken to test whether EGFRvIII also contributes to hypoxia tolerance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0167-8140
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
83
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
333-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17512071-Animals,
pubmed-meshheading:17512071-Cell Hypoxia,
pubmed-meshheading:17512071-Cell Line, Tumor,
pubmed-meshheading:17512071-Drug Delivery Systems,
pubmed-meshheading:17512071-Female,
pubmed-meshheading:17512071-Genetic Variation,
pubmed-meshheading:17512071-Humans,
pubmed-meshheading:17512071-Mice,
pubmed-meshheading:17512071-Mice, Nude,
pubmed-meshheading:17512071-Neoplasms,
pubmed-meshheading:17512071-Radiation Tolerance,
pubmed-meshheading:17512071-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17512071-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance.
|
|
pubmed:affiliation |
Maastricht Radiation Oncology (MAASTRO) Lab, GROW Research Institute, University of Maastricht, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
